Genetic variants of arachidonate 5-lipoxygenase-activating protein, and risk of incident myocardial infarction and ischemic stroke: a nested case-control approach

Recent findings have implicated specific gene polymorphisms of arachidonate 5-lipoxygenase-activating protein (ALOX5AP), and 2 at-risk haplotypes (HapA, HapB) in myocardial infarction and stroke. To date, no prospective data are available. We evaluated 10 specific Icelandic ALOX5AP gene variants amo...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Stroke (1970) Ročník 37; číslo 8; s. 2007
Hlavní autoři: Zee, Robert Y L, Cheng, Suzanne, Hegener, Hillary H, Erlich, Henry A, Ridker, Paul M
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 01.08.2006
Témata:
5-Lipoxygenase-Activating Proteins
Adult
Aged
Aged, 80 and over
Brain Ischemia - genetics
Carrier Proteins - genetics
Case-Control Studies
Genetic Predisposition to Disease - genetics
Genetic Variation
Haplotypes
Humans
Iceland
Male
Membrane Proteins - genetics
Middle Aged
Myocardial Infarction - genetics
Polymorphism, Single Nucleotide
Prospective Studies
Randomized Controlled Trials as Topic
Stroke - genetics
Iceland
ISSN:1524-4628, 1524-4628
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Recent findings have implicated specific gene polymorphisms of arachidonate 5-lipoxygenase-activating protein (ALOX5AP), and 2 at-risk haplotypes (HapA, HapB) in myocardial infarction and stroke. To date, no prospective data are available. We evaluated 10 specific Icelandic ALOX5AP gene variants among 600 male participants with incident atherothrombotic events (myocardial infarction [MI] or ischemic stroke) and among 600 age- and smoking-matched male participants, all white, who remained free of reported cardiovascular disease during follow-up within the Physicians' Health Study cohort. Overall allele, genotype, and haplotype distributions were similar between cases and controls. Single-marker conditional logistic regression analysis adjusted for potential risk factors found no association with risk of atherothrombotic events. Further investigation using a haplotype-based approach showed similar null findings with MI (HapA: odds ratio [OR]=1.18, 95% CI, 0.76 to 1.85; P=0.46; HapB: odds ratio=0.62, 95% CI, 0.36 to 1.07; P=0.08), and with ischemic stroke (HapA: odds ratio=1.11, 95% CI, 0.65 to 1.89; P=0.71; HapB: odds ratio=0.82, 95% CI, 0.47 to 1.42; P=0.47). We found no evidence for an association of the specific Icelandic ALOX5P gene variants/at-risk haplotypes tested with risk of incident MI nor ischemic stroke in this prospective, non-Icelandic study.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1524-4628
1524-4628
DOI:10.1161/01.STR.0000229905.25080.01